Valeo Financial Advisors’s Filana Therapeutics FLNA Stock Holding History

Valeo Financial Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,902	Closed	-$205K	–	600
2022 Q3	$205K	Buy	+4,902	New	+$132K	0.01%	436
2022 Q2	–	Sell	-5,900	Closed	-$219K	–	632
2022 Q1	$219K	Sell	5,900 -1,000	-14%	-$42.4K	0.01%	524
2021 Q4	$302K	Buy	+6,900	New	+$362K	0.02%	409

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Valeo Financial Advisors's FLNA Position: Q4 2022 in Review

Valeo Financial Advisors sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 4,902 shares — an estimated $205K sold.

Valeo Financial Advisors first reported a position in FLNA in Q4 2021 and held it in 3 quarters. The position peaked at $302K in Q4 2021. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

Valeo Financial Advisors reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
Valeo Financial Advisors sold 4,902 Filana Therapeutics shares in Q4 2022, an estimated $205K.
Valeo Financial Advisors first reported a position in Filana Therapeutics in Q4 2021 and held it in 3 quarters.
Valeo Financial Advisors's Filana Therapeutics position peaked at $302K in Q4 2021.
153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Valeo Financial Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.